Clinical trial
Pemetrexed in Patients With Advanced Neuroendocrine Tumors
NCT00424723 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00424723 |
|---|---|
| Title | Pemetrexed in Patients With Advanced Neuroendocrine Tumors |
| Official title | A Phase II Study of Pemetrexed in Patients With Advanced Neuroendocrine Tumors |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroendocrine Tumors |
| Intervention type | Drug |
| Interventions | Pemetrexed |
| Enrollment | 32 |
| Start date | Dec 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Mar 1, 2010 |
| First posted | Jan 19, 2007 |
| Last update posted | Aug 12, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: